Bariticinib (Olumiant; Eli Lilly) is prescribed by the majority of US dermatologists to their patients with alopecia areata (AA), according...
Fewer than half of those dealing with Parkinson’s disease in the United States are able to gain clinical control of...
PHILADELPHIA — Results of a survey conducted in the U.S. and abroad showed that most nephrologists remain wary about prescribing...
With competition finally hitting the US market, branded adalimumab (Humira) is finally losing market share, according to the third quarter update of...
In both the U.S. and Europe, clinicians want to limit treatment with glucocorticoids — steroid hormones whose long-term use for...
Oral drugs have raced to the front of the pack in the crowded migraine therapy space and appear to be...
Spherix Global Insights, a leading provider of market research, conducted a survey using a sample of 81 rheumatologists, 83 gastroenterologists,...
Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at...
As fatty liver disease gets a new name, will it also finally get approved drug treatments? That’s what healthcare professionals...
Genentech’s first campaign for eye drug Vabysmo is literally eye-opening. In the debut TV commercial, a woman opens an eye-shaped...
Although providers are optimistic about the potential of a new treatment for Alzheimer’s, some are concerned that the burden of monitoring the...
U.S. neurologists are “cautiously optimistic” about using Eisai’s Leqembi in Alzheimer’s disease as concerns about safety and the need for...
